Loading...
Market
New hypoparathyroidism treatment announced by another company by end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Public announcements or press releases from pharmaceutical companies
Story
FDA Approves Ascendis Pharma's YORVIPATH for Hypoparathyroidism; Stock Rises 10% Post-Takeda
Aug 12, 2024, 11:40 AM
The U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma's YORVIPATH® (Palopegteriparatide), marking it as the first and only treatment for hypoparathyroidism in adults. This approval positions YORVIPATH as the sole available treatment for this rare hormone disorder in the United States, following the discontinuation of Takeda's previous therapy. The announcement led to a 10% increase in Ascendis Pharma's stock price in premarket trading.
View original story
Similar markets
Takeda • 25%
Amgen • 25%
Novo Nordisk • 25%
Other • 25%
0-25% • 25%
25-50% • 25%
50-75% • 25%
Above 75% • 25%
Haemophilia treatment • 25%
Other rare disease treatment • 25%
Multiple treatments • 25%
No approval • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%